Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | ASH 2014: Phase III Lyma trial of rituximab maintenance after ASCT in mantle cell lymphoma

Bertrand Coiffier • 5 Dec 2014
ASH 2014
Mantle Cell Lymphoma Cisplatin Cytarabine Dexamethasone

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses the first interim analysis of the phase III prospective Lyma study of rituximab maintenance versus wait and watch after four courses of rituximab, dexamethasone, cytarabine and cisplatin (R-DHAP) followed by autologous stem cell transplantation (ASCT) in previously untreated young patients (under 66 years old) with mantle cell lymphom

More from Bertrand Coiffier

2:40
Understanding biosimilars
Bertrand Coiffier • 22 Jun 2017
3:27
Why we need novel strategies for diffuse large B-cell lymphoma
Bertrand Coiffier • 22 Jun 2017
1:28
Biosimilars in oncology: EHA 2017 session on rituximab
Bertrand Coiffier • 22 Jun 2017
0:39
Biosimilars: informing patients and physicians
Bertrand Coiffier • 22 Jun 2017

Related Videos

3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
2:40
The impact of CAR-T on the role of SCT in lymphoma
Anna Sureda • 7 Mar 2024
0:44
A case report of CAR-T-related neurotoxicity presenting as delayed aseptic meningitis in MCL
Stefania Bramanti • 17 Feb 2024
The content of VJHemOnc is intended for healthcare professionals